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Cancer‑associated fibroblasts 
stimulate primary tumor 
growth and metastatic spread 
in an orthotopic prostate cancer 
xenograft model
Johannes Linxweiler1*, turkan Hajili1, christina Körbel2, Carolina Berchem1, 
Philip Zeuschner1, Andreas Müller3, Michael Stöckle1, Michael D. Menger2, Kerstin Junker1,4 & 
Matthias Saar1,4
The unique microenvironment of the prostate plays a crucial role in the development and progression 
of prostate cancer (PCa). We examined the effects of cancer‑associated fibroblasts (CAFs) on PCa 
progression using patient‑derived fibroblast primary cultures in a representative orthotopic xenograft 
model. Primary cultures of CAFs, non‑cancer‑associated fibroblasts (NCAFs) and benign prostate 
hyperplasia‑associated fibroblasts (BPHFs) were generated from patient‑derived tissue specimens. 
These fibroblasts were coinjected together with cancer cells (LuCaP136 spheroids or LNCaP cells) 
in orthotopic PCa xenografts to investigate their effects on local and systemic tumor progression. 
Primary tumor growth as well as metastatic spread to lymph nodes and lungs were significantly 
stimulated by CAF coinjection in LuCaP136 xenografts. When NCAFs or BPHFs were coinjected, tumor 
progression was similar to injection of tumor cells alone. In LNCaP xenografts, all three fibroblast 
types significantly stimulated primary tumor progression compared to injection of LNCaP cells alone. 
CAF coinjection further increased the frequency of lymph node and lung metastases. This is the first 
study using an orthotopic spheroid culture xenograft model to demonstrate a stimulatory effect of 
patient‑derived CAFs on PCa progression. The established experimental setup will provide a valuable 
tool to further unravel the interacting mechanisms between PCa cells and their microenvironment.
Prostate cancer (PCa) is the most frequently diagnosed malignant tumor and the second-leading cause of cancer-
related death in men in developed  countries1–3. Patients diagnosed at an early, organ-confined stage can mostly 
be cured by radical prostatectomy or radiotherapy. However, many patients still present with or progress to 
metastatic  disease4,5, and palliative androgen deprivation therapy (ADT) in combination with the chemothera-
peutic agent docetaxel or the androgen-receptor-signaling inhibitors abiraterone or apalutamide is the standard 
treatment for this  condition6–10. Virtually all patients acquire resistance to ADT after one to ten years progressing 
to castration-resistant prostate cancer (CRPC), for which several life-prolonging palliative treatment options 
are  available11. In addition to its reliance on androgen receptor signaling from organ-confined to metastatic, 
castration-resistant  disease12,13, other hallmarks of PCa are its  multifocality14, its  multiclonality15,16 and its notable 
inter- and intraindividual  heterogeneity17–20; due to these qualities, PCa management is a major challenge, and 
thus, further elucidation of the unique biology of this disease is urgently needed. The unique microenvironment 
(known as the “tumor microenvironment” or “TME”) of the prostate concerning its cellular constitution and 
the concentration of cytokines, growth factors and hormones is an important factor in PCa development and 
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 progression21,22. Regarding the fact that the occurrence of metastases is the most important prognostic factor 
for PCa patients, it would be highly desirable to better understand the contribution of different TME compo-
nents on metastatic PCa progression and how they could serve as prognostic markers or therapeutic targets. 
The PCa TME comprises various components, one of the most important and most intensely studied of which 
are cancer-associated fibroblasts (CAFs). The contribution of CAFs to PCa development and progression was 
demonstrated by several elegant early studies. Olumi et al. showed that the normally non-tumorigenic benign 
prostate hyperplasia (BPH) cell line BPH1 can give rise to PCa-resembling tumors when grafted under the renal 
capsule of immunodeficient mice together with prostate  CAFs23. Gleave and colleagues observed stimulation 
of PCa growth and progression when PCa cells were inoculated together with prostate or bone fibroblasts in 
subcutaneous  xenografts24. Since then, the number of publications on CAFs and their role in PCa has grown 
exponentially. However, the biology of CAF-PCa cell interaction and its implications for the management of PCa 
are still incompletely understood, which might in part be due to the use of suboptimal in vitro and especially 
in vivo model systems.
In previous work, we successfully established orthotopic PCa xenografts that realistically display the intrapro-
static growth of PCa and the development of  metastases25,26. In this study, we aimed to combine this orthotopic 
in-vivo model system with three-dimensional PCa spheroid  cultures27,28 and different patient-derived prostate 
fibroblast primary cultures to investigate the effect of the latter on PCa progression and metastasis.
Methods
Cell culture. LNCaP cells (purchased from DSMZ, Braunschweig, Germany; identity verified by STR profil-
ing) were cultured at 37 °C in RPMI medium (Thermo Fisher, Waltham, MA, USA) supplemented with 10% fetal 
bovine serum (Biochrom, Berlin, Germany) in a humidified environment with 5%  CO2. PC3 cells (purchased 
from DSMZ, Braunschweig, Germany) were cultured at 37 °C in DMEM medium (Thermo Fisher, Waltham, 
MA, USA) supplemented with 10% fetal bovine serum (Biochrom, Berlin, Germany) in a humidified environ-
ment with 5%  CO2. LuCaP136 spheroids were cultured at 37 °C in ultra-low attachment plates (Corning Inc., 
Corning, NY, USA) in an optimized StemPro (Thermo Fisher, Waltham, MA, USA) stem cell  medium27,28 at 
37 °C in a humidified environment with 5%  CO2. Dissociated single cells were regularly removed by filtration 
with Falcon 40 μm cell strainers (Corning, Inc., Corning, NY, USA), and spheroid viability was regularly tested 
using a fluorescence-based live/dead assay (Thermo Fisher, Waltham, MA, USA). LuCaP136 spheroids were 
provided from the Donna Peehl lab (Stanford University, CA, USA). LuCaP136 and LNCaP PCa cells were used 
in this study the way they were primarily established and are normally cultivated, i.e. LuCaP136 as three-dimen-
sional spheroids and LNCaP as monolayer cultures. Representative microscopic images of LuCaP136 spheroids 
and LNCaP cells are shown in Supplementary Fig. 1. To count LuCaP136 cells, the spheroids were digested to 
single cell clusters using Trypsin/EDTA solution (Sigma-Aldrich, St. Louis, MO, USA) under microscopic con-
trol and counted with a Neubauer chamber. Thereafter, the volume containing the cell number to be injected 
was removed and spheroids were allowed to reassemble for 15 min before they were further processed for the 
preparation of in-vivo experiments.
For the generation of CAF or non-cancer-associated fibroblast (NCAF) primary cultures, tumor-bearing 
(CAF) or tumor-free (NCAF) tissue pieces were resected from the same radical prostatectomy specimens by 
an experienced uropathologist immediately after surgery. Sufficient tumor cell content (CAF) or the absence of 
tumor cells (NCAF) was verified through analyses of H&E-stained frozen sections. Thereafter, the tissue was cut 
into small pieces (2–3 mm3), which were then placed in cell culture flasks and covered with Dulbecco´s modi-
fied Eagle’s medium (DMEM; Sigma Aldrich, St. Louis, MO, USA) supplemented with 10% fetal bovine serum 
(Biochrom, Berlin, Germany) in a humidified environment with 5%  CO2 at 37 °C. When the fibroblasts began to 
grow from the tissue pieces, the latter were removed, and these cells were cultivated as conventional monolayer 
cultures. For the generation of BPH-associated fibroblast (BPHF) primary cultures, tissue pieces from transvesi-
cal prostate adenoma enucleation specimens were used and processed as described above for CAF and NCAF 
primary cultures. The patient characteristics of the fibroblast donors are given in the supplement. All patients 
from whom samples were obtained to establish fibroblast primary cultures provided informed consent for the 
use of biological material and clinical data and these experiments were approved by the Ethical Review Board 
of Saarland (references 188/05 and 141/14). All methods done involving human participants were performed 
in accordance with the ethical standards of the institutional committee and with the 1964 Helsinki declaration 
and its later amendments.
For the preparation of cells/spheroids for intraprostatic injection, they were harvested, counted and sus-
pended in a previously prepared, cooled 1:3 mixture of Matrigel HC (Corning, Inc., Corning, NY, USA) and 
culture medium at a density of 5 × 105 cells/10 μl when the PCa cells were injected alone or at a density of 1 × 106 
cells/10 μl (5 × 105 PCa cells plus 5 × 105 fibroblasts) when the PCa cells were injected together with fibroblasts. 
In the latter case, the medium of the PCa cells (RPMI for LNCaP, StemPro medium for LuCaP136) was used 
to prepare the cells (PCa cells and fibroblasts) for injection. This suspension was kept on ice until it was drawn 
up in a cooled 10 μl Hamilton syringe (Hamilton, Reno, NV, USA) immediately before intraprostatic injection.
Immunofluorescence staining. For characterization of the fibroblast primary cultures by immunofluo-
rescence staining, the cells were seeded into 4-well chamber slides (Corning Falcon, Corning, NY, USA) at a 
density of 10,000 cells/well. Twenty-four hours later, the medium was removed, the cells were washed three 
times with phosphate-buffered saline (PBS; Sigma Aldrich, St. Louis, MO, USA) and fixed by 30 min incubation 
with 4% paraformaldehyde at 37 °C. Thereafter, the cells were washed in PBS, and nonspecific protein binding 
sites were blocked by incubation in blocking solution (80 ml Tris/HCl pH 7.2, 20 ml FCS, 3 g BSA) for 30 min 
at room temperature. This step was followed by incubation with primary antibodies diluted in Antibody Diluent 
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(Dako, Glostrup, Denmark) for 1 h at room temperature (mouse anti-Pan-Cytokeratin/1:100/Dako, Glostrup, 
Denmark; rabbit anti-Vimentin/1:100/Cell Signaling Technology, Danvers, MA, USA; mouse anti-αSMA/1:100/ 
Cell Signaling Technology, Danvers, MA, USA), washing in PBS and incubation with secondary antibodies 
diluted in Antibody Diluent (Dako, Glostrup, Denmark) for 1 h at room temperature (goat-anti-mouse IgG-
Alexa594/1:1,000; goat-anti-rabbit IgG-Alexa488/1:500; Jackson ImmunoResearch, Cambridgeshire, UK). 
Finally, after the samples were washed again with PBS, the chambers were removed, the slides were embedded 
with Vectashield DAPI HardSet mounting medium (Vector Laboratories, Burlingame, CA, USA) and inspected 
with a Nikon Eclipse Ci fluorescence microscope and a Nikon digital-sight DS-2MBWc camera unit (Nikon, 
Minato, Japan).
Animals. Male immunodeficient SCID-mice (CB17/lcr-Prkdcscid/lcrlcoCrl, 8–10  weeks old; Charles River 
Laboratories, Sulzfeld, Germany) were kept in isolated ventilated cages under specific pathogen-free conditions 
in a temperature- and humidity-controlled, 12 h dark/light environment at the animal care facility of the Insti-
tute for Clinical and Experimental Surgery at Saarland University. The animals had free access to tap water 
and standard pellet food. Their health status was monitored daily. All experiments were approved by the local 
governmental animal care committee (No. 30/2015) and conducted in accordance with the German legislation 
on the protection of animals and the National Institutes of Health Guide for the Care and Use of Laboratory 
Animals (NIH Publication #85-23 Rev. 1985)25,26.
Orthotopic tumor cell implantation and follow‑up. Intraprostatic tumor cell (+ /− fibroblast) injec-
tion was performed as previously  described25. Briefly, after a lower midline incision and preparation of seminal 
vesicles, prostate and urinary bladder, 10 μl of a 1:3 Matrigel:medium suspension containing 5 × 105 (PCa cells 
alone) or 1 × 106 (5 × 105 PCa cells combined with 5 × 105 fibroblasts) cells were injected into the left anterior 
prostate lobe using a cooled 10  μl Hamilton syringe. For analysis of the orthotopic tumor engraftment and 
growth as well as the development of metastases, all mice underwent high-resolution ultrasonography (hrUS) 
examinations at 3, 4, 5, 6, 8 and 10 weeks, in vivo micro CT (μCT) analyses at 6, 8 and 10 weeks and 9.4 T MRI 
analyses at 6 and 10 weeks after intraprostatic tumor cell injection. The imaging studies (hrUS, μCT, MRI) were 
performed as previously  described25.
Mice were sacrificed after 10 weeks by cervical dislocation. During autopsy, the prostate tumor was resected 
for histological analysis, and the abdominal visceral organs, lungs and lymph nodes were inspected for macro-
scopically visible metastases. In addition to the primary tumor tissue, the lower extremity bones, lungs, liver and 
the renal as well as lumbar aortic lymph nodes were subjected to histological evaluation. Concerning regional 
lymph nodes, we routinely removed the sacral, iliac and lumbar lymph nodes (4–6 lymph nodes per mouse).
Serum PSA measurements. Blood samples were collected from all mice at 4, 6, 8 and 10 weeks after 
intraprostatic injection via puncture of the retrobulbar sinus under general anesthesia with glass microcapillar-
ies (Sigma Aldrich, St. Louis, MO, USA). The PSA levels in mouse serum were analyzed in the core laboratory 
facility of Saarland University Medical Center as previously  described26.
Immunohistochemistry. Immunohistochemistry of the primary tumors and metastases resected during 
autopsy was performed as previously  described25 using human-specific primary antibodies against cytokera-
tin (1:200/Dako, Glostrup, Denmark), Ki67 (Dako, Glostrup, Denmark; 1:200), vimentin (1:100/Cell Signaling 
Technology, Danvers, MA, USA) and Ku70 (1:100/Abcam, Cambridge, UK).
Statistical analyses. Statistical analyses were performed with Excel for Mac V16.15 (Microsoft, Redmond, 
USA), SigmaPlot Version 13 (Systat Software Inc., San Jose, USA) and SPSS Statistics 23 (IBM, Armonk, USA). 
In general, two-tailed statistical tests were performed, and p values < 0.05 were considered statistically signifi-
cant. The serum PSA values are shown in boxplots.
Results
Natural tumor progression in orthotopic LuCaP136 and LNCaP xenografts. To observe the 
natural course of primary tumor growth and the development of metastases in “native” LuCaP136 and LNCaP 
xenografts, we orthotopically injected 5 × 105 LuCaP136 or LNCaP cells in 8 mice for each cell line and moni-
tored local and systemic tumor progression for 10  weeks by small animal imaging analyses and serum PSA 
measurements. The primary tumors showed exponential growth, reaching a median volume of approximately 
120  mm3 for the LuCaP136 tumors and approximately 180  mm3 for the LNCaP tumors after 10 weeks (Suppl. 
Figure 2A). Primary tumor growth was accompanied by an exponential increase in serum PSA values, which 
ranged from 0.1 to 1.5 ng/ml in LuCaP136 xenografts and 5 to 110 ng/ml in LNCaP xenografts (Suppl. Fig-
ure 2B). Notably, the primary tumor volumes determined by high-resolution ultrasonography and serum PSA 
values showed a good correlation, with  r2 values of 0.87 for LuCaP136 xenografts and 0.85 for LNCaP xenografts 
(Suppl. Figure 2C). Histologically, both cell lines gave rise to solid tumors composed of relatively monomorphic 
cells showing a high number of mitotic figures (Suppl. Figure 3). Concerning metastatic seeding, we observed 
regional (iliac and lumbal) lymph node metastases after 10 weeks in 5 of 6 mice in the LuCaP136 group and 4 of 
7 mice in the LNCaP group (Table 1). No metastases in the lungs or other organs were observed in LuCaP136 
xenografts, while lung metastases were present in 1 of 7 animals in the LNCaP group. Two mice in the LuCaP136 
group and one mouse in the LNCaP group died prematurely due to non-cancer-associated causes.
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Generation and characterization of fibroblast primary cultures. CAFs, NCAFs and BPHFs could 
be successfully generated from cancerous (CAFs) and tumor-free (NCAFs) radical prostatectomy tissue speci-
mens as well as from prostate adenoma enucleation specimens (BPHFs). The success rate to generate fibroblast 
primary cultures was close to 100%, and these primary cultures could be kept in culture until passage 20 to 30 
before they became senescent. However, in the experiments described here, all primary cultures were used in 
early passages (1 to 7). Before using these cells for in vivo experiments, we characterized the fibroblast primary 
cultures by immunofluorescence staining. While all fibroblasts stained positive for vimentin and negative for 
Pan-CK, only CAFs showed αSMA expression to varying degrees (15% to 80% of cells). Figure 1 shows repre-
sentative images of the fibroblast primary cultures used for the first in vivo coinjection series described in the 
next section. PC3, which is Pan-CK and vimentin double positive, and LNCaP, which is Pan-CK positive, were 
used as positive controls. Importantly, in all in vivo experiments, the CAFs and NCAFs used in one in vivo series 
Table 1.  Development of lymph node and lung metastases in orthotopic LuCaP136 and LNCaP xenografts. 
10 weeks after intraprostatic injection of 5 × 105 LuCaP136 or LNCaP cells, mice were sacrificed, and their 
organs were examined for the presence of metastases. The number of animals with lymph node and lung 
metastases is given in this table (based on histological examination of the removed organs). Two animals in 
the LuCaP136 and one animal in the LNCaP group (initially n = 8 in both groups) died prematurely due to not 
cancer-specific causes. LN = lymph node.
No LN metastases 1 LN metastasis 2 LN metastases







(n = 6) 1 3 2 0 6 0
LNCaP alone 
(n = 7) 3 3 1 0 6 1
Figure 1.  Characterization of the fibroblast primary cultures used for in vivo coinjection series 1 via 
immunofluorescence staining. The cancer-associated fibroblast (CAF), non-cancer-associated fibroblast 
(NCAF) and benign prostate hyperplasia-associated fibroblast (BPHF) primary cultures used in the first in vivo 
coinjection series (CAF1, NCAF1, BPHF1) were characterized by immunofluorescence staining for the markers 
Pan-cytokeratin, Vimentin and αSMA. PC3 and LNCaP were used as positive controls for vimentin and Pan-CK 
(PC3 vimentin and Pan-CK double positive, LNCaP Pan-CK positive). Scale bar (bright field pictures) = 50 μm. 
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were always generated from the same radical prostatectomy specimen to avoid interindividual “background 
noise” in fibroblast biology.
Effect of orthotopic fibroblast coinjection on tumor progression and the development of 
metastases. In a next step, we performed orthotopic coinjection of prostate cancer cells (LuCaP136 or 
LNCaP) with different fibroblast primary cultures (CAFs, NCAFs, BPHFs), resulting in 6 groups with 8 mice 
each (in vivo coinjection series 1), to examine the effects of fibroblasts on local and systemic PCa progression. 
We observed stimulatory effects of fibroblast coinjection on tumor progression with CAFs showing the strongest 
effects in both xenograft models.
In detail, comparing the primary tumor growth curves from this first in vivo coinjection series (Fig. 2, con-
tinuous lines) with those after injection of LuCaP136 spheroids or LNCaP cells alone (Fig. 2, dashed lines; 
corresponding to the growth curves in Suppl. Figure 2A), we found that fibroblast coinjection had different 
effects on primary tumor growth in LuCaP136 versus LNCaP xenografts. In LuCaP136 xenografts, coinjection 
of CAFs led to significantly higher tumor volumes compared to NCAF and BPHF coinjection. In the latter two 
cases, primary tumor growth was comparable to that following injection of LuCaP136 spheroids alone (Fig. 2A). 
In LNCaP xenografts, CAF, NCAF and BPHF coinjection all resulted in significantly increased tumor volumes 
Figure 2.  Primary tumor growth after coinjection with different fibroblast primary cultures in orthotopic 
LuCaP136 and LNCaP xenografts. Primary tumor growth curves after coinjection with cancer-associated 
fibroblasts (CAF1), non-cancer-associated fibroblasts (NCAF1) or benign prostate hyperplasia-associated 
fibroblasts (BPHF1) in orthotopic LuCaP136 (A) and LNCaP (B) xenografts. The dashed lines represent the 
growth curves when LuCaP136 or LNCaP cells were injected alone. Tumor volumes were determined by high-
resolution 3D ultrasonography. p values were determined by the Mann–Whitney U test (comparison of each 
coinjection group vs. tumor cell alone group). *p < 0.05 **p < 0.01 ***p < 0.001. (C) Representative transversal 
T2-weighted (left) and diffusion-weighted (right; ADC-map) MRI-images of orthotopic xenograft tumors (here: 
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compared to injection of LNCaP cells alone (Fig. 2B). 9.4 T MRI imaging showed solid intraprostatic tumors 
with marked diffusion restriction in all cases (Fig. 2C).
According to the observations in primary tumor volume analyses, serum PSA values were significantly 
higher in the LuCaP136 + CAF1 group than in the LuCaP136 + NCAF1 group and the LuCaP136 + BPHF1 group 
(Fig. 3B). The serum PSA values of the latter two groups were comparable to those when LuCaP136 spheroids 
were injected alone (Fig. 3A). In LNCaP xenografts, again corresponding well to the primary tumor volume 
results, no difference in serum PSA values could be observed between the different coinjection groups (Fig. 3C). 
Compared to the injection of LNCaP cells alone (Fig. 3A), serum PSA values after fibroblast coinjection were 
slightly but not significantly higher.
In addition to the stimulatory effect on primary tumor growth, coinjection of CAFs led to an increased 
frequency of lymph node and lung metastases in LuCaP136 xenografts compared to both, the injection of 
LuCaP136 spheroids alone as well as the coinjection of the other two fibroblast types (Table 2). The presence and 
number of lymph node and lung metastases were confirmed by histopathological examination of the removed 
organs after autopsy. As with primary tumor volumes and serum PSA values, LNCaP xenografts showed no sig-
nificant differences in the occurrence of lymph node and lung metastases after coinjection with CAF1, NCAF1 
or BPHF1 cells. However, the frequency of lymph node and lung metastases was increased especially in the 
LNCaP + CAF1 group though these differences were not statistically significant (Table 2). Representative H&E-
stained microphotographs of lymph node and lung metastases in LuCaP136 and LNCaP xenografts are shown 
in supplementary Fig. 4, immunohistochemical stainings proving their human origin as well as representative 
MRI and CT images in supplementary Fig. 5. Metastases in organs other than the lymph nodes and lungs were 
not observed in this in vivo series.
Validation of the effects of orthotopic fibroblast coinjection in LuCaP136 xenografts. Since 
we observed a stimulation of primary tumor growth as well as metastatic spread by CAFs compared to NCAFs 
and BPHFs in LuCaP136 xenografts in our first in vivo coinjection series, we aimed to validate these results in 
two further in vivo experiments (in vivo coinjection series 2 and 3) using two other sets of fibroblast primary cul-
tures (CAF2/NCAF2/BPHF2 and CAF3/NCAF3/BPHF3, respectively). All fibroblasts showed negative Pan-CK 
and positive vimentin staining, while αSMA was only expressed by CAFs (Suppl. Figure 6). In both validation 
experiments, CAF coinjection again resulted in significantly higher primary tumor volumes and significantly 
higher serum PSA values compared to NCAF or BPHF coinjection (Fig. 4). In the first validation experiment 
(in vivo coinjection series 2), the frequency of lymph node metastases was significantly higher in the CAF2 
coinjection group compared to the NCAF2/BPHF2/LuCaP136 alone groups (each p < 0.05), while in the sec-
ond validation experiment (in vivo coinjection series 3), metastatic spread to lymph nodes was significantly 
stimulated in the CAF3 coinjection group compared to the NCAF3 coinjection group (p = 0.01; CAF3 vs. BPHF3 
and CAF3 vs. LuCaP136 both p = 0.10) (Table 3). The frequency of lung metastases was significantly higher in 
the LuCaP136 + CAF3 group vs. the LuCaP136 + NCAF3 group and the LuCaP136 alone group (both p < 0.05) 
(Table 3).
Immunohistochemistry of orthotopic tumors after coinjection of fibroblast and PCa cells. Pri-
mary tumors harvested during autopsy were subjected to immunohistochemistry using anti-Cytokeratin, anti-
Vimentin and human-specific anti-Ku70 antibodies. While the tumor cells proved to be of epithelial and human 
origin (Cytokeratin positive, Ku70 positive, Vimentin negative), human fibroblasts (expected to be Cytokeratin 
negative, Ku70 positive, Vimentin positive) could not clearly be detected 10  weeks after injection (n = 5 per 
xenograft type; Suppl. Figure 7).
Discussion
For many decades, scientists have mainly focused on cancer cells themselves as the primary target to elucidate 
the biology of cancer and to develop new preventive, diagnostic or therapeutic approaches. However, the pivotal 
importance of the so-called tumor microenvironment (TME) including different cellular and extracellular factors, 
such as blood vessels, lymph vessels, fibroblasts, immune cells and collagen fibers, for nearly all tumor entities, 
including prostate cancer (PCa), has become increasingly evident in recent years. To date, the most intensely stud-
ied PCa TME components are cancer-associated fibroblasts (CAFs). These comprise several fibroblast subtypes 
that arise through continuous mutual interaction with nearby cancer cells and are characterized by the acquisition 
of an activated myofibroblast-like phenotype, the expression of specific markers such as αSMA, FAP or TGF-β 
and other specific molecular  changes29–31. In contrast, genetic aberrations are generally not  observed32. In previ-
ous work, CAFs have been shown to play an important role in many aspects of PCa biology, such as local tumor 
growth and  progression24,33,34, the development of  metastases29,35,36 and the emergence of drug  resistance37,38. 
Accordingly, these cells have also been identified as promising therapeutic  targets39–41 and as potential prognostic 
 markers42. Even so, most of these studies come along with major drawbacks. First, in many studies, immortalized 
fibroblast cultures or fibroblast cultures that are not truly representative for PCa CAFs were used. Second, in vivo 
experiments were mostly performed in subcutaneous or renal subcapsular xenografts. In our opinion, when 
the different biological aspects of prostate cancer-associated fibroblasts are investigated in vivo, it is of utmost 
importance to use a) fibroblast cultures that are well characterized and of human origin (ideally patient-derived 
primary cultures) and b) the orthotopic/intraprostatic grafting site, which represents a unique microenvironment 
with regard to its cellular composition and the local concentration of growth factors and hormones, especially 
testosterone. We consider the latter point to be crucial since prostate CAFs are known to express an androgen 
receptor (AR), which plays an important role for many biological effects exerted by these  cells43–46.
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Figure 3.  Development of serum PSA values after coinjection with different fibroblast primary cultures in 
orthotopic LuCaP136 and LNCaP xenografts. Analysis of the serum PSA values after coinjection with cancer-
associated fibroblasts (CAF1), non-cancer-associated fibroblasts (NCAF1) or benign prostate hyperplasia-
associated fibroblasts (BPHF1) in orthotopic LuCaP136 (B) and LNCaP (C) xenografts. The results from the 
LuCaP136 alone and LNCaP alone groups are shown as well for comparison (A). p values were determined by 
the Mann–Whitney U test. *p < 0.05 **p < 0.01 ***p < 0.001.
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To the best of our knowledge, there is only one recent study in addition to ours that used patient-derived 
fibroblast primary cultures for coimplantation with PCa cells in an orthotopic xenograft model. Mishra and 
colleagues prepared cell recombinants by mixing CWR22Rv1 PCa cells with patient-derived CAFs in collagen 
at a 1:3  ratio38. Primary cultures were defined as CAFs when they led to the development of tumors within four 
weeks after renal subcapsular grafting together with normally non-tumorigenic BPH1 cells (otherwise they 
were termed NAFs), which is a stringent and straightforward method of CAF characterization dating back to 
the pioneering work of Olumi, Hayward and  colleagues23,47. The resulting collagen plugs were then surgically 
implanted into the anterior prostate lobes, and the tumor volumes were measured by calipers after the end point 
of the experiment was reached.
In our study, unlike Mishra et al., we generated pairs of fibroblast primary cultures (CAFs and NCAFs) from 
cancerous and cancer-free tissue areas of the same radical prostatectomy specimens, which were then used 
for intraprostatic coinjection and compared in our orthotopic xenograft model. Therefore, when the effects of 
CAFs and NCAFs were compared, the “background” noise in the biology of these two fibroblast populations 
was minimized compared to that with two entirely different fibroblast cell lines or two cell lines derived from 
different patients. Another aspect that was different from Mishra et al. and unique in our study is that, besides 
LNCaP monolayer cells, we also used a three-dimensional spheroid culture as prostate cancer cell component in 
the orthotopic coinjection experiments. LuCaP136 spheroids were generated from the equally named patient-
derived xenografts (PDX) and are characterized by the expression of a wild-type androgen receptor, loss of both 
PTEN alleles, and absence of the TMPRSS2:ERG fusion gene. When implanted into the tibiae of immunodeficient 
mice, LuCaP136 spheroids give rise to osteosclerotic bone metastases, which respond to  castration27,28,48. Fur-
thermore, we performed repeated noninvasive monitoring of local and systemic tumor burden by small animal 
imaging analyses and repeated serum PSA measurements, which allows the longitudinal observation of tumor 
progression instead of end point measurements only.
In our study, looking at the effect of coinjection of different fibroblasts on primary tumor growth and meta-
static spread in LuCaP136 and LNCaP xenografts, statistically significant results were observed concerning pri-
mary tumor growth in the LuCaP136 + CAF coinjection groups vs. the other three LuCaP136 groups (LuCaP136 
alone/LuCaP136 + NCAF/ LuCaP136 + BPHF) in all three in-vivo series in terms of significantly higher primary 
tumor volumes in the CAF-coinjection groups. In LNCaP xenografts, all coinjection groups (LNCaP + CAF1/ 
LNCaP + NCAF1/ LNCaP + BPHF1) showed significantly higher primary tumor volumes as compared to the 
injection of LNCaP alone while there was no difference between the different fibroblast coinjection groups. PSA 
values were significantly higher in LuCaP136 + CAF vs. LuCaP136 + NCAF and LuCaP136 + BPHF in all three 
in-vivo coinjection series. Therefore, the evidence for a stimulation of primary tumor growth in LuCaP136 
xenografts by CAF-coinjection is very robust. A clear conclusion on the effect of fibroblast coinjection in LNCaP 
xenografts cannot be drawn yet as we only performed one coinjection experiment, which showed a stimulation 
of primary tumor growth by all fibroblasts compared to the injection of LNCaP cells alone but no differences in 
serum PSA values. Concerning metastatic spread we had more heterogeneous results. The number of lymph node 
metastases was significantly higher in LuCaP136 + CAF1 vs. LuCaP136 + NCAF1 (p < 0.03), in LuCaP136 + CAF2 
Table 2.  Development of lymph node and lung metastases after coinjection with different fibroblast primary 
cultures in orthotopic LuCaP136 and LNCaP xenografts. 10 weeks after intraprostatic injection of 5 × 105 
LuCaP136 or LNCaP cells combined with 5 × 105 CAF1, NCAF1 or BPHF1 cells, mice were sacrificed, and 
their organs were examined for the presence of metastases. The number of animals with lymph node and lung 
metastases in each of the 6 resulting groups is given in this table (based on histological examination of the 
removed organs). The results from the first series, in which LuCaP136 and LNCaP cells were injected alone 
(see also Table 1), are added as well. Single animals in different combination groups (initially n = 8 in both 
groups) died prematurely due to not cancer-specific causes. p values were determined by Fisher´s exact test. 
BPHF = benign prostate hyperplasia associated fibroblasts, CAF = cancer-associated fibroblasts, NCAF = non-
cancer-associated fibroblasts, LN = lymph node.
 ≥ 2 LN metastases Statistical significance Lung metastases Statistical significance
LuCaP136 alone (n = 6) 2/6 / 0/6 /
LuCaP136 + NCAF1 (n = 6) 1/6 p = 1,00 (vs. LuCaP136 alone) 0/6 p = 1,00 (vs. LuCaP136 alone)
LuCaP136 + BPHF1 (n = 7) 2/7
p = 1,00 (vs. LuCaP136 alone)
p = 0,63 (vs. 
LuCaP136 + NCAF1)
1/7
p = 1,00 (vs. LuCaP136 alone)
p = 1,00 (vs. 
LuCaP136 + NCAF1)
LuCaP136
 + CAF1 (n = 7) 6/7
p = 0,10 (vs. LuCaP136 alone)
p = 0,03 (vs. 
LuCaP136 + NCAF1)
p = 0,10 (vs. 
LuCaP136 + BPHF1)
4/7
p = 0,07 (vs. LuCaP136 alone)
p = 0,07 (vs. 
LuCaP136 + NCAF1)
p = 0,27 (vs. LuCaP136 + BPHF1)
LNCaP alone (n = 7) 1/7 / 1/7 /
LNCaP + NCAF1 (n = 7) 1/7 p = 1,00 (vs. LNCaP alone) 2/7 p = 1,00 (vs. LNCaP alone)
LNCaP + BPHF1 (n = 7) 2/7 p = 1,00 (vs. LNCaP alone)p = 1,00 (vs. LNCaP + NCAF1) 2/7
p = 1,00 (vs. LNCaP alone)
p = 1,00 (vs. LNCaP + NCAF1)
LNCaP + CAF1 (n = 7) 4/7
p = 0,27 (vs. LNCaP alone)
p = 0,27 (vs. LNCaP + NCAF1)
p = 0,59 (vs. LNCaP + BPHF1)
5/7
p  = 0,10 (vs. LNCaP alone)
p = 0,29 (vs. LNCaP + NCAF1)
p = 0,29 (vs. LNCaP + BPHF1)
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vs. LuCaP136 + NCAF2/ LuCaP136 + BPHF2/ LuCaP136 alone (each p < 0.05) and in LuCaP136 + CAF3 vs. 
LuCaP136 + NCAF3 (p = 0.01). The frequency of lung metastases was significantly higher in LuCaP136 + CAF3 
vs. LuCaP136 + NCAF3 and LuCaP136 alone (both p < 0.05). A non-significant trend towards a higher frequency 
of lung metastases was seen in LuCaP136 + CAF1 vs. LuCaP136 + NCAF1/ LuCaP136 alone (both p = 0.07). So 
in conclusion, a significant stimulation of metastatic spread to lymph nodes and lungs by CAF-coinjection in 
LuCaP136 xenografts was observed in some but not all comparisons. In LNCaP xenografts there were no statisti-
cally significant effects though the absolute numbers observed in the different groups look promising (for example 
lung metastases in 5/7 animals in the LNCaP + CAF1 group vs. 1/7 in the LNCaP alone group and both 2/7 in 
the LNCaP + NCAF1 and the LNCaP + BPHF1 group). To get more reliable results on the stimulation of meta-
static spread to lymph nodes and lungs, the number of mice should be higher in future validation experiments.
An interesting observation was the differential effect of the diverse fibroblast populations on primary tumor 
growth and metastatic spread to regional lymph nodes and lungs in LuCaP136 and LNCaP xenografts. In 
LuCaP136 xenografts, CAFs stimulated primary tumor growth, while NCAF and BPHF coinjections had no 
effect compared to the injection of LuCaP136 cells alone. In contrast, in LNCaP xenografts, CAF, NCAF and 
BPHF coinjections all stimulated primary tumor growth in a similar manner compared to the injection of LNCaP 
cells alone with no difference between the different fibroblast subtypes. Concerning the influence of fibroblast 
coinjection on the development of metastases, we observed a stimulation of metastatic spread to regional lymph 
nodes and lungs by CAF coinjection compared to injection of tumor cells alone as well as the coinjection with 
the other two fibroblast types in both xenograft types though only the results in LuCaP136 xenografts were 
statistically significant (as described in detail above). The reasons for these different effects – especially the ones 
observed on primary tumor growth—in LuCaP136 and LNCaP xenografts remain elusive. In contrast to the 
characteristics of LuCaP136 spheroids, which are described above, LNCaP cells grow as conventional monolayer 
culture, are androgen-sensitive, express an androgen receptor with a point mutation in the ligand binding domain 
leading to a broad steroid binding specificity and show no engraftment when injected intratibially. Hence, due 
to its three-dimensional growth and its biological characteristics, LuCaP136 might be the more representative 
in-vitro model. For future studies it may be interesting to also use LNCaP cells as three-dimensional spheroids 
and to analyze if this makes a difference regarding local and metastatic progression or the effect of fibroblast 
coinjection. However, in this pilot study we decided to use both cell lines in the form in which they were originally 
established and are stably growing in vitro. Of note, while both cell lines express PSA but have a quite different 
PSA-density (with LuCaP136 spheroids secreting much less PSA), PSA-values correlated well with sonographic 
tumor volumes in both xenografts enabling longitudinal tracking of tumor burden even when sophisticated small 
animal imaging tools are not available (Suppl. Figure 2C).
While the differential effects of fibroblast coinjection seen in LuCaP136 and LNCaP xenografts are interesting 
observations deserving further investigation, this was not the major focus of our study. As we primarily aimed to 
establish a representative orthotopic in vivo model in which the biological effects of cancer-associated fibroblasts 
can be further investigated, we further focused on LuCaP136 xenografts in our validation experiments since we 
observed the strongest effects of CAF coinjection there in the first coinjection experiment. We cannot directly 
proof if the observed stimulation of metastatic spread in CAF-groups is a direct effect of CAF coinjection or 
more a consequence of increased primary tumor size. However, though both factors may play a role for the 
increased incidence of metastases, we believe the first point to be biologically more important. While in some 
tumors like renal cell carcinoma the incidence of metastases is clearly correlated with primary tumor  size49 this 
is not the case for prostate cancer. In contrast, it has been shown in several studies that CAFs are able to stimulate 
metastasis-associated biological features in nearby PCa cells like invasion, epithelial-to-mesenchymal transition 
(EMT), angiogenesis and stemness  traits33–36,50,51.
When we examined the retrieved primary tumors by H&E histology as well as immunohistochemistry after 
ten weeks of follow-up, we could no longer observe human fibroblasts. This observation is consistent with the 
findings from PDX models, in which the human stromal cells are gradually and finally completely replaced by 
murine  equivalents52,53. In addition, these results indicate that the fibroblast-induced effects observed in our 
study might occur early in the disease course, when the coinjected human fibroblasts are still present, which 
explains the early separation of the growth curves observed in LuCaP136 xenografts. To see stronger effects of 
CAFs and observe their effect over a longer time frame, one might either have to increase the fibroblast : cancer 
cell ratio as Mishra et al. did in their study (3:1)38 or use immortalized fibroblasts, which may show longer in-vivo 
survival compared to patient-derived primary cultures but are on the other hand less biologically representa-
tive. Additionally, to further elucidate the dynamic process of microenvironment remodeling (replacement of 
human fibroblasts by murine equivalents), it could be considered to sacrifice animals at different time points 
after coinjection and examine the retrieved tumors by immunohistochemistry or FACS analyses.
In our study, we detected an increased rate of lymph node and lung metastases after intraprostatic coinjection 
of CAFs, an interesting observation that deserves further investigation. While robust experimental evidence has 
shown the stimulatory effect of CAFs on primary tumor growth, little is known about their role in local progres-
sion and metastatic spread of  PCa54. They might contribute to these processes, for example, by the secretion of 
matrix metalloproteinases or extracellular  vesicles55–57. However, the molecular mechanisms involved in these 
complex interactions are still unclear to date.
In our study, we used small animal imaging (high-resolution 3D ultrasonography, in-vivo micro-CT, 9.4 T 
MRI) and histological/immunohistochemical evaluation of the removed organs to monitor metastatic pro-
gression. While these sophisticated tools allow for a sensitive and specific detection of most metastases, other 
techniques like bioluminescence or PCR for human-specific Alu-sequences could further improve the detection 
and exact quantification of metastatic disease in such a model.
Finally, the term “cancer-associated fibroblasts” probably refers to a fairly heterogeneous group of CAF sub-
types that remain to be clearly characterized molecularly and functionally to improve our understanding of their 
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Figure 4.  Validation of the effects of orthotopic fibroblast coinjection in LuCaP136 xenografts on primary 
tumor growth and serum PSA values using two further sets of fibroblast primary cultures [CAF2/NCAF2/
BPHF2 (A and C) and CAF3/NCAF3/BPHF3 (B and D)]. Primary tumor growth curves (A, B) and serum 
PSA values (C, D) after coinjection with cancer-associated fibroblasts (CAF), non-cancer-associated fibroblasts 
(NCAF) or benign prostate hyperplasia-associated fibroblasts (BPHF) in orthotopic LuCaP136 xenografts are 
shown. The results from the LuCaP136 alone group are shown as well. Tumor volumes were determined via 
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role in TME – cancer cell  interactions58–60. While some groups tried to classify CAFs into distinct subgroups (e.g. 
CAF 1, 2 and 3), we believe such a categorization to be somewhat arbitrary as the evolution of CAFs during the 
progression of PCa is probably a continuous, spatially and temporally heterogeneous process. Accordingly, our 
primary cultures can be expected to be a mixture of different CAF subtypes and we did not further characterize 
them by staining additional markers (e.g. FAP, CD49b, FSP1) since these results would have no influence on 
the key messages of our study. Nonetheless, a deeper molecular characterization of a panel of fibroblast primary 
cultures including the ones used in this study has been previously done on the gene expression level showing 
dysregulated expression of various genes in CAFs compared to NCAFs and  BPHFs61. For example, the genes 
SDF1, TGFβ, PDGFRβ and FAP were significantly upregulated in CAFs (Suppl. Figure 8)61. Apart from that, after 
having established a valuable in vivo model to examine the effects of CAFs on PCa progression in this study, it 
may be worthwhile to focus in detail on the differential role of putative CAF subtypes in future investigations.
In conclusion, we for the first time successfully established a versatile in vivo model that representatively 
displays the stimulatory effects of cancer-associated fibroblasts on prostate cancer progression by combining 
three-dimensional spheroids, patient-derived fibroblast primary cultures and orthotopic xenografts. This model 
provides a valuable tool to further unravel the molecular mechanisms involved in the crosstalk between cancer 
cells and their microenvironment, which plays an important role in prostate cancer progression, metastatic 
spread and therapeutic response.
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